Business
TME Pharma Announces Successful Next Step in Its NOX-E36 Ophthalmology Strategy With Signature of Option Framework Agreement With Singapore Eye Research Institute (SERI)
BERLIN, June 18, 2025--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617731821/en/
About this update from Tme Pharma N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":313,"url":"https://media.zenfs.com/en/business-wire.com/9f08677baeda40ca81bc5a4bcbd36c63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C8leM_aXuH8GhcHCf_mzTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9f08677baeda40ca81bc5a4bcbd36c63","width":960,"height":300},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0eBwwljawkvGkERDFIq74g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD02MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9f08677baeda40ca81bc5a4bcbd36c63","width":1000,"height":313}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1997,"height":708,"url":"https://media.zenfs.com/en/business-wire.com/6c18cae69f9d663bf579e2860c1d828a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/N.pEVtHr8ZnAZSLRCtTBvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6c18cae69f9d663bf579e2860c1d828a","width":960,"height":340},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/oak9EUfL31x8lSDLbsvo2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6c18cae69f9d663bf579e2860c1d828a","width":1200,"height":425}}},{"type":"list","items":[{"val":[{"type":"text","content":"Option framework agreement with SERI establishes ownership- and revenue-sharing model for all NOX-E36 ophthalmic disease rights","length":127,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TME Pharma to lead commercial discussions for potential spin-out or out-licensing","length":81,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"SERI to lead first proof-of-concept Phase 1b study of NOX-E36 in ophthalmology","length":78,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TME Pharma demonstrates continued ability to advance its asset portfolio during the period of strategic transition","length":114,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":400,"olType":false},{"type":"text","content":"BERLIN, June 18, 2025--(BUSINESS WIRE)--Regulatory News:","length":56,"tagName":"p"},{"type"...